Hepatocellular carcinoma organoids enable drug discovery and combination therapy across heterogeneous tumors.
A biobank of patient‑derived HCC organoids coupled with a high‑throughput screening platform identified over 1,600 compounds with antitumor activity and rationally designed regorafenib‑based doublets and triplets that enhance efficacy across heterogeneous tumors, supporting combination therapy strategies.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Quercetin suppresses the progression of HBV-associated hepatocellular carcinoma by modulating the EGFR signaling pathway
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- Surgical treatment of hepatocellular carcinoma: expert consensus statement
- Loco-regional treatment of hepatocellular carcinoma
- Real‑World Outcomes of Atezolizumab‑Bevacizumab in Hepatocellular Carcinoma: The Prospective French CHIEF Cohort